RedHill Biopharma Ltd. (RDHL)
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $5.3M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.3M
- Shares outstanding
- 8.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 7, 2013
RedHill Biopharma Ltd. (RDHL) Stock Price
- Trading 75% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RedHill Biopharma Ltd..
Write a review
News about RedHill Biopharma Ltd.
News & sentiment via Polygon.io
RedHill Biopharma Ltd.: frequently asked questions
Is RedHill Biopharma Ltd. an American company?
RedHill Biopharma Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is RedHill Biopharma Ltd. publicly traded?
Yes — RedHill Biopharma Ltd. is a publicly traded company. Its stock trades under the ticker symbol RDHL on the NASDAQ.
What does RedHill Biopharma Ltd. do?
RedHill Biopharma Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
